Bausch + Lomb (BLCO)
(Delayed Data from NYSE)
$16.43 USD
+0.43 (2.69%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $16.46 +0.03 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Bausch + Lomb (BLCO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.86 | $25.00 | $16.00 | 24.13% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Bausch + Lomb comes to $19.86. The forecasts range from a low of $16.00 to a high of $25.00. The average price target represents an increase of 24.13% from the last closing price of $16.00.
Analyst Price Targets (14)
Broker Rating
Bausch + Lomb currently has an average brokerage recommendation (ABR) of 1.93 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.93 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 46.67% and 13.33% of all recommendations. A month ago, Strong Buy made up 46.67%, while Buy represented 13.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BLCO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 2 | 2 | 2 | 1 | 1 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Strong Buy |
8/1/2024 | Needham & Company | David Saxon | Hold | Hold |
8/1/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Hold | Hold |
7/22/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/10/2024 | Raymond James | Gary Nachman | Not Available | Moderate Buy |
6/11/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
2/26/2024 | Not Identified | Not Identified | Hold | Hold |
2/21/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/16/2023 | Guggenheim Securities | Yatin Suneja | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.93 |
ABR (Last week) | 1.93 |
# of Recs in ABR | 15 |
Average Target Price | $19.86 |
LT Growth Rate | 18.00% |
Industry | Medical Services |
Industry Rank by ABR | 159 of 253 |
Current Quarter EPS Est: | 0.16 |